From a comparative analysis of 5 different molecules in 6 European countries, it is possible to assess that French prices are among the lowest, but this seems to have no consequences on the overall pharmaceutical expenses.
VIENS, G. (1992). Le médicament dans les dépenses de santé : le cas de l'Europe. Journal d'Economie Médicale, pp. 359-363.